Thymalfasin

Mechanism

The pharmaceutical-grade, registered drug form of Thymosin Alpha-1 — a thymus-derived immune peptide. Sold under the brand name Zadaxin, it is approved in over 35 countries primarily for treating hepatitis B and C. The standard dose is 1.6 mg injected under the skin twice per week. It is the same molecule as thymosin-alpha-1 but produced under pharmaceutical manufacturing standards.

Effects

IMMUNE SYSTEM: Thymalfasin (Thymosin Alpha-1, Tα1) is a 28-amino acid peptide originally isolated from thymic tissue (thymosin fraction 5) and produced as a synthetic pharmaceutical (Zadaxin) [pharmacological]. Primary mechanism: activates dendritic cells via TLR9 signaling, enhancing antigen presentation to T-cells and promoting Th1 polarization (IFN-γ, IL-2, IL-12 production) [in vitro, animal]. Stimulates T-cell maturation from pre-T cells in the thymus and periphery — increases CD4+ and CD8+ T-cell numbers and function [clinical, animal]. Enhances NK cell cytotoxicity by 2-4 fold [in vitro, clinical]. Restores immune competence in immunosuppressed states (chemotherapy, HIV, aging, sepsis) — particularly effective at recovering T-cell function when the thymus is involuted [clinical studies]. HEPATITIS: Antiviral immune enhancement — promotes clearance of HBV and HCV by boosting virus-specific T-cell responses rather than direct antiviral action [RCT]. In chronic hepatitis B: increases HBeAg seroconversion rate to 40-50% when combined with interferon, vs. 25-30% with interferon alone [RCT, meta-analyses]. ONCOLOGY: Immune adjuvant for cancer therapy — enhances anti-tumor T-cell responses when combined with chemotherapy, immunotherapy, or vaccines [RCT]. Improves survival when combined with dacarbazine in metastatic melanoma [RCT — Garaci et al., 2007]. Reduces chemotherapy-induced immunosuppression — maintains lymphocyte counts and function during cytotoxic treatment [clinical]. SEPSIS/CRITICAL CARE: Improves survival in severe sepsis by restoring immune paralysis — reduces 28-day mortality in septic patients with immunosuppression phenotype (low HLA-DR on monocytes) [RCT — Wu et al., 2013]. COVID-19: Used extensively in China and Italy during the pandemic for severe COVID-19 — retrospective data suggests reduced mortality in critically ill patients, likely via restoration of lymphocyte function [retrospective studies, case series]. ANTI-INFLAMMATORY: Paradoxically anti-inflammatory despite being immunostimulatory — promotes regulatory T-cell function and IDO (indoleamine 2,3-dioxygenase) expression, preventing excessive inflammation while enhancing specific immunity [in vitro, animal].

Practitioner Guide

ADMINISTRATION: Subcutaneous injection. Zadaxin is supplied as lyophilized powder (1.6 mg per vial) with diluent for reconstitution. Inject SC in the arm, abdomen, or thigh. STANDARD DOSING: 1.6 mg SC twice weekly (Monday/Thursday or Tuesday/Friday) — this is the most established regimen used in clinical trials and approved in 35+ countries. Duration varies by indication: Hepatitis B: 6-12 months. Cancer adjuvant: throughout chemotherapy cycles, typically 6-12 months. Immune reconstitution: 3-6 months, reassess. Sepsis: 1.6 mg SC daily for 5-7 days (acute dosing). HEPATITIS B PROTOCOL: Thymalfasin 1.6 mg SC 2x/week + peginterferon alfa-2a 180 mcg/week for 24-48 weeks. Alternative: thymalfasin + nucleos(t)ide analog (entecavir or tenofovir) in patients who cannot tolerate interferon. Monitor HBV DNA, HBeAg, HBsAg, ALT monthly during treatment. CANCER ADJUVANT PROTOCOL: 1.6 mg SC 2x/week starting 3 days before chemotherapy cycle and continuing through treatment. Monitor absolute lymphocyte count, CD4/CD8 ratio monthly. Some oncologists increase to 3x/week during active chemotherapy. IMMUNE RECONSTITUTION (GENERAL): For chronic illness, aging-related immune decline, or post-chemotherapy recovery: 1.6 mg SC 2x/week for 3-6 months. Assess: total lymphocyte count, CD4/CD8 ratio, NK cell function. Repeat courses as needed with 1-2 month breaks between courses. STACKING: Combine with zinc (30 mg/day — T-cell cofactor), vitamin D (2000-5000 IU/day — immune modulation), selenium (200 mcg/day — selenoprotein support for T-cells), and medicinal mushrooms (reishi, turkey tail — complementary immune support). SAFETY: Remarkably well-tolerated — the safety profile across thousands of patients in clinical trials and decades of commercial use is clean. Most common side effects: injection site discomfort (mild), transient low-grade fever (rare). No significant drug interactions identified. No immunosuppressive rebound after discontinuation. CONTRAINDICATIONS: Immunosuppressive therapy for organ transplant recipients (risk of graft rejection from enhanced T-cell function). Active autoimmune disease in flare (theoretical risk of exacerbation). REGULATORY STATUS: Approved in 35+ countries (not FDA-approved — Zadaxin was never submitted for FDA review as a strategic decision by the manufacturer). Available internationally, particularly in China, Southeast Asia, Latin America, and parts of Europe. SOURCING: Pharmaceutical-grade Zadaxin from SciClone Pharmaceuticals (now Sorrento Therapeutics). Research-grade thymosin alpha-1 available from peptide suppliers.

Evidence

• A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection

  Shehadeh F et al. (2023) — J Infect Dis — PMID: 36056913

  In a prospective randomized pilot trial of 49 hospitalized COVID-19 patients with hypoxemia and lymphocytopenia, thymalfasin increased day-5 CD4+ T-cell counts among low-flow oxygen patients and showed numerically faster clinical recovery without treatment-related serious adverse events, though efficacy signals were not statistically definitive.

  moderate

Research Summary

TIER 1: Multiple RCTs in chronic hepatitis B — meta-analysis (Zhang & Wang, 2006): thymalfasin alone or combined with interferon significantly increases HBeAg seroconversion. RCTs in hepatitis C showing improved sustained virological response when combined with interferon + ribavirin. Garaci et al., 2007 — RCT: thymalfasin + dacarbazine improved survival in metastatic melanoma. Wu et al., 2013 — RCT: thymalfasin in severe sepsis improved 28-day survival (26% mortality vs. 35% control). Approved in 35+ countries for hepatitis B/C and as cancer immunoadjuvant. TIER 2: Systematic reviews of thymalfasin in hepatitis B (multiple meta-analyses confirming benefit). Reviews of thymalfasin as cancer immunoadjuvant across tumor types. Preclinical and clinical reviews of thymosin alpha-1 immunobiology (Romani et al., 2012). COVID-19 retrospective analyses from China and Italy suggesting mortality reduction in severe cases. Reviews of thymalfasin in sepsis and critical care immunosuppression. TIER 3: Widespread clinical experience from Asia (China, where Zadaxin is extensively used), particularly in hepatitis B management. Practitioner protocols for immune reconstitution from integrative medicine clinics. International infectious disease specialist experience. Case series of thymalfasin in HIV co-infection with hepatitis. KEY FINDINGS: Thymalfasin is one of the most clinically validated immune-modulating peptides globally, with RCT-level evidence across hepatitis, cancer, and sepsis. Its clean safety profile and dual action (immunostimulatory + anti-inflammatory) make it unique. The lack of FDA approval is a strategic/commercial gap, not an evidence gap. COVID-19 revived global interest. GAPS: No Phase III FDA-registration trials. Head-to-head comparisons with modern immunotherapies (checkpoint inhibitors) lacking. Optimal duration of therapy not established for most indications. Biomarkers predicting responders not validated. ACTIVE TRIALS: COVID-19 trials (multiple, globally). Cancer immunotherapy combination studies. Sepsis immunomodulation trials.